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Abstract
Background: EpCAM (CD326) is encoded by the tacstd1 gene and expressed by a variety of normal and malignant epithelial
cells and some leukocytes. Results of previous in vitro experiments suggested that EpCAM is an intercellular adhesion
molecule. EpCAM has been extensively studied as a potential tumor marker and immunotherapy target, and more recent
studies suggest that EpCAM expression may be characteristic of cancer stem cells.
Methodology/Principal Findings: To gain insights into EpCAM function in vivo, we generated EpCAM 2/2 mice utilizing an
embryonic stem cell line with a tacstd1 allele that had been disrupted. Gene trapping resulted in a protein comprised of the N-
terminus of EpCAM encoded by 2 exons of the tacstd1 gene fused in frame to bgeo. EpCAM +/2 mice were viable and fertile
and exhibited no obvious abnormalities. Examination of EpCAM +/2 embryos revealed that bgeo was expressed in several
epithelialstructuresincludingdevelopingears(otocysts),eyes,branchialarches, gut, apicalectodermal ridges, lungs,pancreas,
hair follicles and others. All EpCAM 2/2 mice died in utero by E12.5, and were small, developmentally delayed, and displayed
prominent placental abnormalities. In developing placentas, EpCAM was expressed throughout the labyrinthine layer and by
spongiotrophoblastsaswell.PlacentasofEpCAM2/2embryos werecompact,withthinlabyrinthinelayerslackingprominent
vascularity. Parietal trophoblast giant cells were also dramatically reduced in EpCAM 2/2 placentas.
Conclusion: EpCAM was required for differentiation or survival of parietal trophoblast giant cells, normal development of the
placental labyrinth and establishment of a competent maternal-fetal circulation. The findings in EpCAM-reporter mice suggest
involvement of this molecule in development of vital organs including the gut, kidneys, pancreas, lungs, eyes, and limbs.
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Introduction
Epithelial cell adhesion molecule, EpCAM (CD326), (also termed
EGP-2, Egp314, Ep-CAM, GA733-2, gp40, Ly74, panepithelial
glycoprotein 314, TROP1, and tumor associated calcium transducer-
1 (TACSTD1)), isaputativeadhesionmolecule. EpCAM wasinitially
described as a cell surface protein that was selectively expressed by
epithelial [1–3] and some myeloid cancers [4], but it is also expressed
in a variety of normal epithelia including skin, thymus, and gut, in
adult mice and humans [5–7]. Fibroblasts (L cells) that were
transiently transfected with cDNA encoding EpCAM formed
aggregates in suspension [8], suggesting that EpCAM functioned as
a homophilic adhesion molecule. A subsequent study in which L cells
were transfected with cDNAs encoding E-cadherin alone or E-
cadherin and EpCAM suggested that EpCAM attenuated
E-cadherin-mediated adhesion [8,9]. Localization of EpCAM on
polarized epithelial cells in situ indicated that the protein accumulated
predominantly at intercellular basolateral interfaces that were in close
apposition, but that it was excluded from desmosomes and perhaps
tight junctions as well [10,11].
Enrichment of EpCAM in tetraspanin enriched microdomains
(TEMs) that contain b1-integrins, CD44v, claudins and tetra-
spanins [11–13] is also consistent with the concept that EpCAM is
involved in intercellular adhesion, but TEM-associated proteins
have also been implicated in cell signaling and more complex
processes including cell migration and metastasis [14]. Indeed,
Maetzel et al recently described proteolytic fragments of EpCAM
that participated in nuclear signaling in tumor cells [15]. It has also
been reported that EpCAM was expressed by stem cells in colon
cancers [16] and hepatocellular carcinomas [17,18]. Studies
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suggested that EpCAM expression distinguished cells with stem-
like properties from cells that were more differentiated [18]. In
addition, selective knockdown of EpCAM in hepatocellular
carcinoma stem cells attenuated their ability to form tumors in
immunocompromised mice and, even more strikingly, to metas-
tasize [16,18]. The extent to which these latter findings might
relate to modulation of intercellular adhesion is uncertain.
We became interested in EpCAM after determining that,
among dendritic cells, EpCAM was selectively expressed by
epidermal Langerhans cells (LC) [5,19], a distinctive resident skin
leukocyte subpopulation with some epithelial characteristics.
Because EpCAM function is incompletely characterized, and the
functional activities of dendritic cells are best studied in vivo,w e
sought to explore the function of this molecule in EpCAM-
deficient mice. We identified an embryonic stem (ES) cell line with
an EpCAM (tacstd1) mutation created by gene trapping, and used
Figure 1. Disruption of the tacstd1gene that encodes murine
EpCAM. Theschematicindicatesthesiteofinsertionofthegenetrapping
vector as well as thestructureofthe mRNAthat encodestheEpCAM/bgeo
fusion protein.Locationsofprimers usedforgenotypingarealsodepicted.
doi:10.1371/journal.pone.0008543.g001
Figure 2. Expression of EpCAM during embryonic development. (A–D) Whole mount LacZ staining (A&C, in blue) and in situ hybridization
(B&D, in purple) of E9.5 (A&B) and E11.5 (C&D) embryos. EpCAM expression in the apical ectodermal ridges (arrowheads), around the eyes (arrows)
and inter-somitic regions (asterisks) is highlighted in C and D. Corresponding transverse sections with LacZ and light H&E staining (E, G, I), and
immunofluorescence staining using rat anti-mouse EpCAM mAb (F, H, J, in green). OC=otocyst, BC=1
st branchial cleft, Ph=pharynx, HD=hindgut
diverticulum. (K–T) EpCAM expression in epithelia in a variety of organs at E14.5. K, M, O, Q, and S show LacZ and N, P, R, T show immunofluorescence
staining. Primordial hair follicles are prominently stained in the E14.5 embryo as determined by LacZ staining (K&M), in situ hybridization (L), and
immunofluorescence (N). M to T shows EpCAM expression in skin (M&N), nasal plexus (O&P), lungs (Q&R), and kidneys (S&T). Bars=100 mm. HF=hair
follicle, HP=hair placode, OE=olfactory epithelium, BT=bronchiolar tubules, LS=lung saccules, UB=ureteric bud branches.
doi:10.1371/journal.pone.0008543.g002
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ized. EpCAM 2/2 mice exhibited early embryonic lethality with
markedly abnormal placental development. Although many
mechanistic aspects of EpCAM function remain to be elucidated,
these results indicate that this protein is critical for normal
placental development and plays one or more non-redundant roles
in normal epithelial physiology.
Materials and Methods
Generation of EpCAM-Deficient Mice
A mouse ES cell line containing an inserted gene trapping
construct in tacstd1 (RST556, strain 129P2), the gene encoding
EpCAM, was developed by BayGenomics (San Francisco, CA), a
consortium of research groups supported by the National Heart,
Lungand Blood Institute [20]. The gene-trap vector used (pGT0, 1,
2tm-pfs) contained a splice-acceptor sequence, en-2, upstream of a
transmembrane domain that is fused in frame with the reporter
gene/selectable marker bgeo (itself a fusion protein with b-
galactosidase and neomycin phosphotransferase II activities) [20].
Using59rapidamplification ofcDNA ends [21],weverified that the
insertional mutation in RST556 was located in the third intron of
tacstd1. This mutation resulted in the production of an in frame
fusion transcript consisting of exons 1 (untranslated region), 2, and 3
from tacstd1, a CD2-derived transmembrane domain, and bgeo. ES
cells were microinjected into C57BL/6 recipient blastocysts to
generate chimeras that transmitted the mutated allele to progeny in
the Center for Cancer Research Knockout Mouse Core Facility
[22]. EpCAM +/2 mice were then inter-crossed to obtain
homozygous deficient animals. For determination of embryonic
ages, noon on the day of the post-coital plug was taken to be E0.5.
Wild type and heterozygous littermates were used as controls as
indicated. All mice were bred and housed in a pathogen-free
environment and used in experiments in accordance with
institutional guidelines at the Center for Cancer Research, National
Cancer Institute, National Institutes of Health. All experimental
procedures conducted in this study were approved by the Animal
Care and Use Committee, Center for Cancer Research, National
Cancer Institute, National Institutes of Health.
Genotyping
The following primers were used for genotyping: 59-
GCTCCAAACGTGAGTAAATCAATC-39 (EpCAM wild-type
forward; WT 1), 59-TGGAAAGGCGATGACAGTAACG-39
(EpCAM wild-type reverse; WT 2) for the wild-type allele, and
59- CACTCCAACCTCCGCAAACT-39 (EpCAM mutant
reverse; KO 1) in conjunction with the wild-type forward primer
to detect the mutant allele. Because the primer pair that amplified
bgeo gave identical results but yielded more robust signals, the
following primers were subsequently used to detect mutant alleles:
59-TTCACTGGCCGTCGTTTTACAACGTCGTGA- 39 (bgeo
forward; KO 2), 59-ATGTGAGCGAGTAACAACCCGTCG-
GATTCT-39 (bgeo reverse; KO 3).
b-galactosidase Staining
To ascertain EpCAM expression patterns, whole embryos were
stained with a b-galactosidase staining kit (Invitrogen) in
accordance with the manufacturer’s instructions. In brief, embryos
were fixed in 2% glutaldehyde/2% paraformaldehyde for 15–
60 min depending on the age of embryo, stained overnight with
X-gal solution, and post-fixed with 4% PFA.
Laser Capture Microdissection
Embryonic tissue was acquired from formalin-fixed, paraffin-
embedded tissue sections via laser capture microdissection (LCM)
using the Veritas microdissection system (MDS Analytical Technol-
Table 1. EpCAM expression patterns in various organs during embryonic development.
Embryonic stage EpCAM-expressing tissues
E9.5 Ear, brachial arch, pharynx, gut
E11.5 Limb ventral ectoderm, apical ectodermal ridge, ear, whole GI tract, intersomitic junction, eye, pharynx
E14.5 Ear, hair follicle, limb ectoderm, eye, nasal/turbinate, lung, kidney, pancreas, GI tract
doi:10.1371/journal.pone.0008543.t001
Table 2. Distribution of genotypes in viable pups resulting
from matings of EpCAM +/2 mice.
EpCAM genotype
Litter Number
Number of
viable pups +/+ +/2 2/2
17 1 6 0
22 0 2 0
36 2 4 0
45 3 2 0
51 0 4 6 0
65 3 2 0
71 0 6 4 0
81 4 4 1 0 0
95 4 1 0
10 2 1 1 0
11 2 0 2 0
12 12 5 7 0
13 5 1 4 0
14 7 4 3 0
15 4 2 2 0
16 3 1 2 0
17 5 3 2 0
18 4 2 2 0
19 5 1 4 0
20 4 0 4 0
21 3 1 2 0
22 7 3 4 0
23 8 4 4 0
24 5 3 2 0
Total Number (%) 140 (100%) 58 (41%) 82 (59%) 0 (0%)
doi:10.1371/journal.pone.0008543.t002
EpCAM in Placental Development
PLoS ONE | www.plosone.org 3 December 2009 | Volume 4 | Issue 12 | e8543ogies) in the Center for Cancer Research Laser Capture Microdis-
section core facility.Genomic DNA waspurified with QIAamp DNA
micro kits (Qiagen) and genotypes were determined by PCR.
Immunofluorescence Microscopy
The following antibodies were used for immunofluorescence
microscopy: anti-EpCAM (10 mg/ml; clone G8.8, Developmental
Hybridoma Bank, University of Iowa), anti-E-cadherin (10 mg/ml;
ECCD-2, Invitrogen), anti-P-cadherin (10 mg/ml; PCD-1, Invi-
trogen), and anti-PL-1 (10 mg/ml; Santa Cruz Biotech). The
polyclonal anti-Dlx3 antibody was described previously [23].
Antigen retrieval was performed as described [24]. Briefly,
formalin-fixed, paraffin-embedded tissue sections were deparaffi-
nized and subjected to 562 min cycles of microwave treatment in
citrate buffer (pH 6) and allowed to cool to room temperature.
Antigen-retrieved or frozen sections were blocked with 3% milk
(Bio-Rad) and 5% goat or donkey serum in addition to mouse IgG
(10 mg/ml) for 1 hr at room temperature. Primary antibodies were
incubated overnight at 4uC, sections were washed, and bound
antibodies were detected with AlexaFluor-labeled anti-goat, anti-
rabbit, or anti-rat secondary antibodies (5 mg/ml; Invitrogen).
Stained sections were mounted in Prolong Gold with DAPI
(Invitrogen) and analyzed. Immunofluorescence images were
collected and visualized with an AxioImager A1 imunofluores-
cence microscope (Zeiss) and Axiovision software version 4.6
(Zeiss). Intensity levels of digital images in experimental and
control specimens were adjusted proportionally and in the linear
range either in Axiovison or Photoshop CS2 (Adobe).
In situ hybridization. A 950 bp EpCAM cDNA fragment
was inserted into BamHI-EcoRI sites of pcDNA3 (Invitrogen).
Antisense Digoxigenin-labeled RNA probes were synthesized with
Table 3. Time course of lethality in EpCAM 2/2 mice.
EpCAM genotype
Age N= +/+ +/2 2/2 [dead]
E9.25-9.75 36 (4)* 7 13 16 [0]
E10.5-10.75 42 (6)* 10 22 10
{ [5]
E11.5 28 (5)* 9 10 9
{ [5]
E12.5 14 (3)* 5 9 0
{most remaining live embryos developmentally arrested at E10.5-10.5.
*number of litters examined in parentheses.
doi:10.1371/journal.pone.0008543.t003
Figure 3. Developmental delay in EpCAM-deficient embryos. (A) Embryonic development in wild type, haplosufficient and EpCAM-deficient
littermate embryos (E9.5). Arrows indicate open neural tube. Sagittal sections show EpCAM (bgeo) expression in gut endoderm in EpCAM +/2 and
EpCAM 2/2 embryos (arrowheads). The embryos depicted were littermates and photos of whole mounts were taken at identical magnifications. (B)
Genotypes of embryos depicted in (A).
doi:10.1371/journal.pone.0008543.g003
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mount in situ hybridization was carried out using an established
protocol [25] with a short proteinase K treatment (2 mg/ml
proteinase K for 5 min).
Results
Generation of Mice with a Mutated tacstd1 Allele
Generation of knockout mice by gene trapping involves random
insertion of a construct that includes an splice acceptor that
efficiently ‘‘traps’’ one or more upstream exons by incorporating
them into a fusion protein encoded by a cDNA immediately
downstream of the splice acceptor site. In the vector used in the
present study, the cDNA downstream of the splice acceptor site
encodes a portion of CD2 (inclusive of the transmembrane
domain) in frame with a fusion protein that retains b-galactosidase
and neomycin phosphotransferase activities (bgeo). Because
expression of the fusion protein that results from gene trapping
is expected to occur only in cells in which the targeted locus is
being actively transcribed, the pattern and intensity of expression
of bgeo can be studied as a surrogate marker for expression of the
protein encoded by the targeted gene.
After searching the Baygenomics database (see International
gene trap consortium, http://www.genetrap.org/), we identified
four ES cell lines that were predicted to include the gene trapping
vector inserted in the gene encoding EpCAM (tacstd1). For this
study, we utilized ES cell line RST556 that contained the trapping
construct inserted into the third intron of tacstd1 (Fig. 1). A
chimeric male founder mouse was generated and crossed to
normal C57BL/6 mice to generate heterozygous mice containing
one copy of the mutated EpCAM allele. Mice were genotyped
using PCR as described in the Materials and Methods. EpCAM
+/2 mice were viable, healthy, grossly indistinguishable from
their wildtype littermate counterparts, and were fertile.
Expression of EpCAM in Multiple Organs during
Development
Evaluation of EpCAM expression using LacZ staining at E8.5
revealed a pattern that was predominantly endodermal (data not
shown), consistent with recent reports that indicated that EpCAM
can be used as a marker to enrich endodermal cells from early
embryos [26]. At E9.5, EpCAM expression was most prominent in
the facial primordia, gut, branchial arches, and otocyst (Fig. 2A, B).
Corresponding transverse sections revealed concordant expression
of EpCAM as demonstrated by LacZ or immunofluorescence
staining using anti-EpCAM antibody (Fig. 2E–I, F–J). At E11.5 and
earlier, the periocular region, theapicalectodermalridge precursors
(ventral limb ectoderm) and mature ridge, and inter-somitic regions
in the posterior trunk/tail stained positive (Fig. 2C, D). Particularly
prominent expression was evident in developing hair follicles in
whole mounts prepared at E14.5 (Fig. 2K–N). In analogy to what
has previously been reported in rats [27], EpCAM expression was
readilydetectedinsome epithelial componentsofa varietyoforgans
including hair follicles, the nasal plexus, lungs, kidneys, and
pancreas examined at E14.5 (Fig. 2K–T, Table 1).
Embryonic Lethality in EpCAM-Deficient Mice
EpCAM +/2 mice were intercrossed to generate homozygous
deficient animals. No EpCAM 2/2 pups were identified in .24
litters born to .10 breeding pairs (see Table 2). Examination of
embryos of various gestational ages revealed that EpCAM 2/2
embryos appeared to develop normally up to E8.5, after which
development arrested, and became nonviable during E10.5-E11.5
(Table 3). EpCAM2/2 embryos with gestational ages $E12.5 were
not identified. At E9.5, EpCAM 2/2 embryos were significantly
smaller than EpCAM-sufficient siblings and sometimes exhibited
delayed, incomplete neural tube closure (Fig. 3). Localization of bgeo
in whole mounts and sagittal sections of E9.5 EpCAM-deficient
embryos revealedintensestainingofotocysts, branchialarches andgut.
EpCAM Expression in Developing Placenta
Although EpCAM was widely expressed in developing embryos,
the early embryonic lethality that we detected suggested the
possibility of an extra-embryonic cause. To address this possibility,
Figure 4. Defective placental development in the absence of
EpCAM. (A) EpCAM expression in wild type C57BL/6 placentas at E 9.5 as
shown by immunofluorescence staining (left). Bar=200 mm. Right panel
shows a schematic of E9.5 placenta. La=labyrinth, Sp=spongiotropho-
blasts, TGC=parietal trophoblast giant cells, V=vasculature. (B) Morphol-
ogy in H&E stained sections of EpCAM +/2 and 2/2 placentas. Bars=50
and 20 mm. Panels on the right represent high power view of insets in the
left panels. Arrow in B highlights intravascular microthrombus.
doi:10.1371/journal.pone.0008543.g004
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Localization of EpCAM in frozen tissue from E8.5 and E9.5
placentas using immunofluorescence microscopy revealed expres-
sion in the allantois, the labyrinthine layer, and in spongiotropho-
blasts as well (Fig. 4A & 5C). The highest levels of expression were
detected in the labyrinth. Interestingly, vascular structures in the
maternal decidua also stained strongly for EpCAM.
To preserve spatial relationships and obtain optimal placental
morphology, we embedded embryos in utero and prepared
sections from formalin-fixed, paraffin-embedded tissues. Placen-
tas were subsequently genotyped using embryo-derived genomic
DNA that was obtained from adjacent sections using laser-
capture microdissection. E8.5 EpCAM 2/2 extra-embryonic
tissues showed no obvious abnormality (data not shown). As
shown in Fig. 4B, whereas well-developed labyrinthine layers
with obvious villi were present in E9.5 EpCAM +/2 placentas,
placentas from EpCAM 2/2 mice were small, the labyrinthine
layer was thin and villous formation was limited. EpCAM 2/2
placentas were also notable for markedly decreased frequencies of
parietal trophoblast giant cells. In addition, micro-thrombi were
observed in surrounding capillaries adjacent to the chorionic
plate in some EpCAM 2/2 placentas, suggesting impaired fluid
flow or hypercoagulability.
EpCAM 2/2 Placentas Contain Decreased Numbers of
Parietal Trophoblast Giant Cells
To better characterize cellular constituents of EpCAM 2/2
placentas, tissue sections of E9.5 placentas were stained for
placental lactogen-1 (PL-1) and Dlx3, markers that identify
parietal trophoblast giant cells and the labyrinth, respectively
[28]. PL-1 positive parietal trophoblast giant cells were normally
represented in EpCAM +/2 placentas, but they were dramatically
reduced in number in EpCAM-deficient tissue (Fig. 5A). The
differences were particularly striking in an example of fraternal
twin embryos, one EpCAM 2/2 and the other EpCAM +/2,i n
a single uterine decidual swelling (Fig. 5B). Consistent with the
morphology observed in hematoxylin- and eosin-stained sections
(Fig. 4B), the Dlx3-expressing labyrinth layer thickness was
markedly reduced in EpCAM 2/2 embryos (Fig. 5A). Dlx3
was clearly expressed, however, and the levels of expression in
EpCAM 2/2 tissue may exceed that present in normal placentas.
To directly address the issue of EpCAM expression by parietal
trophoblast giant cells, we stained frozen sections with anti-
EpCAM antibodies and DAPI. Interestingly, EpCAM was not
detected on parietal trophoblast giant cells (Fig. 5C).
Distribution of EpCAM and Cadherins in Developing
Placenta
Because previous studies suggested that EpCAM might
modulate cadherin function [10,29], we characterized E9.5
placentas for expression of EpCAM, E-cadherin and P-cadherin.
EpCAM was co-expressed with E-cadherin throughout the
labyrinth, with the highest levels of EpCAM expression occurring
on cells in closest proximity to the embryonic chorionic plate
(Fig. 6A). In striking contrast, expression of EpCAM was inversely
correlated with P-cadherin expression, which was selectively
expressed by spongiotrophoblasts. E-cadherin and P-cadherin
were reciprocally expressed in the labyrinth, but appeared to be
co-expressed in the spongiotrophoblast layer.
To determine if placental cadherin expression might be
perturbed in the absence of EpCAM, we stained formalin-fixed,
paraffin-embedded sections from EpCAM +/2 and EpCAM 2/
2 placentas for E- and P-cadherin after antigen retrieval.
Although the labyrinth was clearly abnormal in EpCAM 2/2
placentas, E-cadherin was expressed throughout (Fig. 6B). P-
cadherin distribution was not obviously different in EpCAM-
deficient as compared with EpCAM-sufficient placentas.
Figure 5. Diminished parietal trophoblast giant cell population in EpCAM 2/2 placentas. (A) Sections of E9.5 placenta double-stained
with anti-Dlx3 antibody and anti-PL-1 antibody after antigen retrieval. (B) Anti-PL-1 staining of a section that contained two embryos (EpCAM 2/2,
upper embryo; EpCAM +/2, lower embryo) in one E9.5 uterine decidual swelling. (C) EpCAM and DAPI staining of a frozen section of an E9.5 wild type
placenta. Bars=50 (A), 200 (B), and 20 mm (C).
doi:10.1371/journal.pone.0008543.g005
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in Other Tissues
The co-expression of EpCAM and E-cadherin and the reciprocal
expression that we observed with P-cadherin in placenta was striking.
To determine if these relationships were maintained in EpCAM-
expressing epithelia in other developing organs, we surveyed skin, gut
and lung in E14.5 mice using immunofluorescence microscopy. We
observed that E-cadherin and EpCAM were concordantly expressed
in developing gut, and P-cadherin and EpCAM were reciprocally
expressed (Fig. S1A). In developing lung, most (but not all) E-
cadherin-expressing developing bronchi also expressed P-cadherin
(Fig. S1B). Those that did not express P-cadherin stained for
EpCAM,andtherewasnooverlapbetweenEpCAMandP-cadherin
expression. In developing hair follicles, EpCAM and E-cadherin were
concordantly expressed by superficial epithelial cells, while P-
cadherin staining was most intense on basal cells (Fig. S1C).
Discussion
We generated EpCAM-deficient mice to gain additional insights
into EpCAM function in vivo. We utilized a pre-existing ES stem cell
clone [20,30] with a targeted allele producing a fusion protein that
contained a short N-terminal portion of EpCAM in addition to bgeo.
Consistent with results previously reported in rat embryos [27], we
determined that EpCAM was expressed in a variety of epithelial
structures, including apical ectodermal ridges, signaling centers that
are essential for limb bud outgrowth. In all epithelial tissues
examined, EpCAM and E-cadherin were expressed by the same
cells, whereas EpCAM was reciprocally expressed with P-cadherin.
No viable EpCAM 2/2 pups were obtained. Examination of
embryos obtained after timed heterozygote matings revealed that
2/2 embryos implanted, and that control and EpCAM-deficient
embryos could not be distinguished on or before E8.5. By E9.5,
however, EpCAM knockout embryos were smaller than EpCAM
sufficient embryos, neural tube closure was often delayed, and all
EpCAM knockout embryos became nonviable before E12.5. Our
observation of prominent EpCAM expression in the early placenta
prompted us to look for extraembryonic abnormalities. Studies of
implantation sites in situ revealed that placentas associated with
EpCAM 2/2 embryos were small and thin, the latter
characteristic reflecting more compact labyrinthine layers that
did not exhibit prominent villous formation or vascularity.
Numbers of parietal trophoblast giant cells were also strikingly
diminished in EpCAM-deficient placentas. Localization of Ep-
CAM in E8.5 and E9.5 placentas revealed that the protein was
highly expressed by trophoblasts in the labyrinthine layer and also
by spongiotrophoblasts. EpCAM was not detected on parietal
trophoblast giant cells, suggesting the possibility of a nonauton-
omous effect on giant cell number.
In light of previous studies implicating EpCAM as a modulator
of E-cadherin-mediated adhesion [9,29], it is interesting to
compare the phenotypes of EpCAM- and cadherin-deficient mice.
E-cadherin-deficient embryos do not form trophectoderm or
blastocysts and do not implant [31,32]. Although both E-cadherin
and EpCAM are widely expressed in early embryos and in
developing epithelia, post-implantation placental abnormalities
were the most striking changes identified in the setting of EpCAM
deficiency. P-cadherin is abdundant in placenta and is frequently
expressed in developing and adult epithelia, but P-cadherin-
deficient mice were viable, fertile, and they did not exhibit obvious
epithelial abnormalities [33]. It has been suggested that the ability
of E-cadherin to compensate for loss of P-cadherin in many tissues
may explain the unexpectedly mild phenotype of P-cadherin-
deficient mice. Clearly, EpCAM has one or more important
functions that cannot be compensated by other proteins, including
E-cadherin.
The embryonic lethality of EpCAM deficiency may reflect an as
yet uncharacterized global effect on epithelial cell physiology, or a
requirement for EpCAM in the development or survival of a
critical placental cell type. The diminished frequency of parietal
trophoblast giant cells is among the most striking histologic
abnormalities in EpCAM-deficient placentas. Parietal trophoblast
giant cells are the first cells to differentiate from the trophoecto-
derm, but they may also derive from trophoblasts and spongio-
trophoblasts via endoreplication [34]. Parietal trophoblast giant
cells invade into the uterine wall, establishing a receptive
Figure 6. Cadherin expression in EpCAM-sufficient and defi-
cient placentas. (A) Frozen sections from E9.5 wild type placentas
stained for EpCAM, E-, and P-cadherins (La=labyrinth). (B) Sections from
formalin-fixed, paraffin-embedded tissues stained for E-cadherin and P-
cadherin after antigen retrieval. Bars=20 mm.
doi:10.1371/journal.pone.0008543.g006
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interface via elaboration of paracrine factors including VEGF,
metalloproteinases, hormones and cytokines [35,36]. Alternatively,
the embryonic lethality seen in our study may be secondary to
parietal trophoblast giant cell deficiency, since null mutations in
Hand1 (a basic helix-loop-helix transcription factor that enhances
parietal trophoblast giant cell development) and I-mfa (an inhibitor
of Mash2, a basic helix-loop-helix protein that inhibits parietal
trophoblast giant cell development) both lead to parietal
trophoblast giant cell deficiency, arrested placental development
and embryonic lethality [37,38]. Because EpCAM-deficient
placentas were smaller and the labyrinthine layers were thinner
and less elaborate than in controls, impaired placental develop-
ment in this setting may reflect a more global effect on epithelial
cell physiology. EpCAM is expressed by embryonic stem cells [39]
and cancer stem cells [16,17,40], and it is possible that EpCAM
influences trophoblast stem cell behavior.
In future studies, it will be of interest to explore other potential
roles of EpCAM in vivo. These studies will require generation of
mice that carry EpCAM alleles that can be targeted in selected
lineages and/or at selected times. The importance of elucidating
EpCAM function in vivo is highlighted by recent studies that
demonstrate that at least some cases of congenital tufting
enteropathy, a rare, typically autosomal recessive syndrome that
is characterized by intractable infantile diarrhea, result from
mutations in the gene encoding EpCAM [41]. Intrauterine demise
or abnormal fertility has not been reported in families of patients
with congenital tufting enteropathy, but it may be significant that
null mutations in the gene encoding EpCAM, or mutations that
resulted in truncated EpCAM protein, have not yet been identified
in patients. The mutations identified to date may be hypomorphs
that result in identifiable abnormalities in some EpCAM-
expressing epithelia (eg intestinal epithelia and perhaps ocular
conjunctiva), but not others. The availability of conditional
knockout mice and transgenic mice that express candidate
hypomorphic EpCAM alleles will allow EpCAM function to be
additionally explored in embryonic development, reproduction,
and adult physiology. Recent experiments in zebrafish implicate
EpCAM in epithelial morphogenesis during epiboly and skin
development [42], suggesting that future studies of conditional
EpCAM knockout mice will be informative.
Supporting Information
Figure S1 Co-expression of EpCAM and E-cadherin and
reciprocal expression with P-cadherin in epithelia in developing
non-placental tissues. EpCAM, E-cadherin and P-cadherin were
stained in frozen sections from E14.5 embryos in the (A) gut, (B)
lungs (BT=bronchiolar tubules, LS=lung saccules), (C) and hair
follicles. EpCAM and E-cadherin expression is present in gut
epithelium, and P-cadherin is expressed in muscular/serosal layers
in (A). Bars=100 mm (A&B), and 20 mm (C).
Found at: doi:10.1371/journal.pone.0008543.s001 (7.94 MB
TIF)
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